An evaluation of enucleation in the management of uveal melanomas - PubMed (original) (raw)
Review
An evaluation of enucleation in the management of uveal melanomas
L E Zimmerman et al. Am J Ophthalmol. 1979 Jun.
Abstract
Uveal melanomas are slow growing tumors that may infiltrate out of the eye, mainly following ciliary vessels or nerves, or invade blood vessels, but only rarely do they produce metastatic disease before discovery and treatment. There are, however, large gaps in our knowledge of the frequency and rate of growth of small tumors to those of moderate or large size. We have estimated the mortality from untreated uveal melanomas to be 1% per year or less. Almost all information concerning prognostic factors has been gained from studies based on cases treated by enucleation. The same information is not necessarily applicable to untreated tumors. A study of deaths from metastatic uveal melanomas reveals a striking relationship to enucleation, regardless of whether one deals with cases in which the eye had been symptomatic for a long or short time. Following a low preoperative mortality of 1% or less, the annual mortality rises to about 4% during the first year and then peaks at 8 to 12% during the second year, tapering off during the next three to five years to return to a remarkably constant level of 1 to 2% thereafter. We postulated that this relationship of peak mortality to enucleation is attributable mainly to an often overwhelming dissemination of tumor cells taking place during surgery or to a lowering of the host's immunologic defense mechanisms as a consequence of the operation, or both. We urge the pooling of all available information gained from clinical studies made on untreated tumors and recommend prospective studies of a variety of other methods of treating uveal melanomas in addition to the standard enucleation.
Similar articles
- Observation of suspected choroidal and ciliary body melanomas for evidence of growth prior to enucleation.
Gass JD. Gass JD. Ophthalmology. 1980 Jun;87(6):523-8. doi: 10.1016/s0161-6420(80)35200-7. Ophthalmology. 1980. PMID: 7413141 - An evaluation of enucleation in the management of uveal melanomas.
Zimmerman LE, McLean IW. Zimmerman LE, et al. Int Ophthalmol Clin. 1980 Summer;20(2):1-31. Int Ophthalmol Clin. 1980. PMID: 6995381 Review. No abstract available. - Statistical analysis of follow-up data concerning uveal melanomas, and the influence of enucleation.
Zimmerman LE, McLean IW, Foster WD. Zimmerman LE, et al. Ophthalmology. 1980 Jun;87(6):557-64. doi: 10.1016/s0161-6420(80)35196-8. Ophthalmology. 1980. PMID: 7413145 - Survival rates after enucleation of eyes with malignant melanoma.
Seigel D, Myers M, Ferris F 3rd, Steinhorn SC. Seigel D, et al. Am J Ophthalmol. 1979 Jun;87(6):761-5. doi: 10.1016/0002-9394(79)90349-0. Am J Ophthalmol. 1979. PMID: 453304 - Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells.
Zimmerman LE, McLean IW, Foster WD. Zimmerman LE, et al. Br J Ophthalmol. 1978 Jun;62(6):420-5. doi: 10.1136/bjo.62.6.420. Br J Ophthalmol. 1978. PMID: 352389 Free PMC article. Review.
Cited by
- Past, Present, and Future of Ocular Oncology in India.
Bansal R. Bansal R. Indian J Surg Oncol. 2022 Dec;13(Suppl 1):101-103. doi: 10.1007/s13193-022-01646-z. Epub 2022 Sep 14. Indian J Surg Oncol. 2022. PMID: 36691505 Free PMC article. No abstract available. - Primary Sites of Uveal Melanoma Associated with Distinct Survival Outcomes and Clinicopathological Features: A SEER Population-Based Study of 4359 Cases.
Liang X, Rong Y, Wang J, Zhang H. Liang X, et al. Int J Gen Med. 2021 Sep 4;14:5221-5232. doi: 10.2147/IJGM.S328910. eCollection 2021. Int J Gen Med. 2021. PMID: 34512005 Free PMC article. - Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference.
Smith JR, Pe'er J, Belfort RN, Cardoso F, Carvajal RD, Carvalho C, Coupland SE, Desjardins L, Francis JH, Gallie BL, Gombos DS, Grossniklaus HE, Heegaard S, Jager MJ, Kaliki S, Ksander BR, Maeurer M, Moreno E, Pulido JS, Ryll B, Singh AD, Zhao J, Parreira A, Wilson DJ, O'Brien JM. Smith JR, et al. Transl Vis Sci Technol. 2018 Jan 9;8(1):9. doi: 10.1167/tvst.8.1.9. eCollection 2019 Jan. Transl Vis Sci Technol. 2018. PMID: 30652059 Free PMC article. - Is Collaborative Ocular Melanoma Study (COMS) still relevant?
Honavar SG. Honavar SG. Indian J Ophthalmol. 2018 Oct;66(10):1385-1387. doi: 10.4103/ijo.IJO_1588_18. Indian J Ophthalmol. 2018. PMID: 30249817 Free PMC article. No abstract available. - Low-dose brachytherapy strategies to treat uveal melanoma: is less more?
Oellers P, Mruthyunjaya P. Oellers P, et al. Melanoma Manag. 2016 Mar;3(1):13-22. doi: 10.2217/mmt.15.34. Epub 2016 Feb 17. Melanoma Manag. 2016. PMID: 30190869 Free PMC article. Review.